NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.50
  • Forecasted Upside: 22.92 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$24.00
▲ +0.34 (1.44%)

This chart shows the closing price for SNDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syndax Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNDX

Analyst Price Target is $29.50
▲ +22.92% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $29.50, with a high forecast of $35.00 and a low forecast of $21.00. The average price target represents a 22.92% upside from the last price of $24.00.

This chart shows the closing price for SNDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Syndax Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022The Goldman Sachs GroupLower Price TargetBuy$40.00 ➝ $35.00Low
7/28/2022B. RileyReiterated RatingBuy$31.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$51.00 ➝ $40.00Low
4/11/2022HC WainwrightInitiated CoverageBuy$31.00Low
2/15/2022The Goldman Sachs GroupInitiated CoverageBuy$37.00High
10/12/2021Morgan StanleyBoost Price TargetEqual Weight$20.00 ➝ $21.00Low
5/25/2021CitigroupInitiated CoverageBuyHigh
5/13/2021Robert W. BairdReiterated RatingBuy$30.00High
5/12/2021Morgan StanleyLower Price TargetEqual Weight$25.00 ➝ $20.00High
4/21/2021B. RileyReiterated RatingBuyHigh
4/21/2021Robert W. BairdLower Price TargetOutperform$39.00 ➝ $30.00High
2/18/2021B. RileyInitiated CoverageBuy$30.00High
12/8/2020Smith Barney CitigroupBoost Price TargetBuy$23.00 ➝ $31.00Low
12/7/2020Morgan StanleyBoost Price TargetEqual Weight$17.00 ➝ $25.00Medium
12/7/2020BTIG ResearchBoost Price TargetBuy$26.00 ➝ $32.00Medium
12/7/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $31.00High
12/2/2020Stifel NicolausInitiated CoverageBuy$32.00High
11/19/2020BarclaysBoost Price TargetOverweight$23.00 ➝ $29.00Low
11/4/2020Morgan StanleyBoost Price TargetEqual Weight$16.00 ➝ $17.00High
5/29/2020Morgan StanleyLower Price TargetEqual Weight$22.00 ➝ $16.00Low
5/25/2020NomuraReiterated RatingBuy$31.00Low
5/22/2020HC WainwrightDowngradeBuy ➝ Neutral$25.00 ➝ $15.00High
5/22/2020BarclaysLower Price TargetOverweight$25.00 ➝ $23.00High
5/22/2020CitigroupUpgradeNeutral ➝ Buy$26.00 ➝ $23.00High
5/21/2020Morgan StanleyBoost Price TargetEqual Weight$10.00 ➝ $22.00Low
5/18/2020CitigroupDowngradeBuy ➝ Neutral$26.00Low
5/11/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $25.00Medium
5/8/2020NomuraBoost Price Target$16.00 ➝ $31.00High
4/30/2020NomuraReiterated RatingBuy$16.00High
4/28/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $19.00High
4/28/2020Robert W. BairdBoost Price TargetOutperform$27.00 ➝ $33.00High
4/21/2020HC WainwrightReiterated RatingBuy$18.00Low
3/26/2020Nomura SecuritiesReiterated RatingBuy$16.00Medium
3/12/2020CitigroupBoost Price Target$12.00 ➝ $18.00High
3/11/2020Morgan StanleyBoost Price TargetEqual Weight$8.00 ➝ $10.00Medium
3/4/2020HC WainwrightReiterated RatingBuy$18.00High
3/4/2020Robert W. BairdBoost Price TargetOutperform$20.00 ➝ $27.00High
3/4/2020BarclaysInitiated CoverageOverweight$15.00High
2/3/2020HC WainwrightReiterated RatingBuy$17.00Low
1/13/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $17.00High
12/10/2019HC WainwrightReiterated RatingBuy$15.00Low
11/8/2019CowenReiterated RatingBuyLow
10/9/2019B. RileySet Price TargetBuy$14.00Low
8/11/2019Nomura SecuritiesReiterated RatingBuy$16.00Low
8/8/2019CowenReiterated RatingBuyHigh
7/16/2019HC WainwrightReiterated RatingBuyLow
3/8/2019Morgan StanleySet Price TargetHold$5.00Medium
3/8/2019B. RileySet Price TargetBuy$26.00Medium
3/8/2019Nomura SecuritiesBoost Price TargetBuy$16.00High
3/8/2019BTIG ResearchLower Price TargetBuy$19.00Medium
3/8/2019HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $16.00High
1/8/2019B. RileyInitiated CoverageBuy$40.00Medium
1/4/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformHigh
12/18/2018Nomura SecuritiesLower Price TargetBuy$22.00 ➝ $12.00Low
10/29/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$6.00High
10/26/2018HC WainwrightLower Price TargetBuy$23.00High
10/11/2018CitigroupLower Price TargetBuy$15.00 ➝ $12.00Medium
7/12/2018HC WainwrightInitiated CoverageBuy$30.00High
3/14/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$25.00 ➝ $24.00High
1/18/2018B. RileyReiterated RatingBuy$40.00High
1/5/2018B. RileyInitiated CoverageBuy ➝ Buy$40.00High
8/14/2017Nomura InstinetReiterated RatingBuy$27.00 ➝ $22.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/13/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/12/2022

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Syndax Pharmaceuticals logo
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Read More

Today's Range

Now: $24.00
Low: $23.81
High: $24.82

50 Day Range

MA: $19.33
Low: $15.60
High: $24.28

52 Week Range

Now: $24.00
Low: $13.27
High: $25.71

Volume

682,553 shs

Average Volume

586,660 shs

Market Capitalization

$1.35 billion

P/E Ratio

150.01

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Syndax Pharmaceuticals?

The following Wall Street research analysts have issued reports on Syndax Pharmaceuticals in the last year: B. Riley, HC Wainwright, Morgan Stanley, StockNews.com, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for SNDX.

What is the current price target for Syndax Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Syndax Pharmaceuticals in the last year. Their average twelve-month price target is $29.50, suggesting a possible upside of 22.9%. The Goldman Sachs Group, Inc. has the highest price target set, predicting SNDX will reach $35.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $21.00 for Syndax Pharmaceuticals in the next year.
View the latest price targets for SNDX.

What is the current consensus analyst rating for Syndax Pharmaceuticals?

Syndax Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNDX will outperform the market and that investors should add to their positions of Syndax Pharmaceuticals.
View the latest ratings for SNDX.

What other companies compete with Syndax Pharmaceuticals?

How do I contact Syndax Pharmaceuticals' investor relations team?

Syndax Pharmaceuticals' physical mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company's listed phone number is (781) 419-1400 and its investor relations email address is [email protected] The official website for Syndax Pharmaceuticals is www.syndax.com. Learn More about contacing Syndax Pharmaceuticals investor relations.